Chemistry Reference
In-Depth Information
[21] Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M., and Leeson, P. D. (2003). A compar-
ison of physiochemical property profiles of development and marketed oral drugs.
Journal of
Medicinal Chemistry
46
, 1250-1256.
[22] Shelat, A. A., and Guy, R. K. (2007). The interdependence between screening methods and
screening libraries.
Current Opinion in Chemical Biology
11
, 244-251.
[23] Robertson, J. G.
(2005). Mechanistic basis of enzyme-targeted drugs.
Biochemistry
44
, 5561-5571.
[24] Robertson, J. G. (2007). Enzymes as a special class of therapeutic target: clinical drugs and
modes of action.
Current Opinion in Structural Biology
17
, 674-679.
[25] Drews, J. (2000). Drug discovery: a historical perspective.
Science
287
, 1960-1964.
[26] Hajduk, P. J., Huth, J. R., and Fesik, S. W. (2005). Druggability indices for protein targets
derived from NMR-based screening data.
Journal of Medicinal Chemistry
48
, 2518-2525.
[27] Hajduk, P. J., Huth, J. R., and Tse, C. (2005). Predicting protein druggability.
Drug Discovery
Today: Targets
10
, 1675-1682.
[28] Cheng,A. C., Coleman, R. G., Smyth, K. T., Cao, Q., Soulard, P., Caffrey, D. R., Salzberg,A. C.,
and Huang, E. S. (2007). Structure-based maximal affinity model predicts small-molecule
druggability.
Nature Biotechnology
25
, 71-75.
[29] Oslob, J. D., and Erlanson, D. A. (2004). Tethering in early target assessment.
Drug Discovery
Today: Targets
3
, 143-150.
[30] Wunberg, T., Hendrix, M., Hillisch, A., Lobell, M., Meier, H., Schmeck, C., Wild, H., and
Hinzen, B. (2006). Improving the hit-to-lead process: data-driven assessment of drug-like and
lead-like screening Hits.
Drug Discovery Today
11
, 175-180.
[31] Egner, U., Kratzschmar, J., Kreft, B., Pohlenz, H. D., and Schneider, M. (2005). The target
discovery process.
ChemBioChem
6
, 468-479.
[32] Becattini, B., and Pellechia, M. (2006). SAR by ILOEs: an NMR-based approach to reverse
chemical genetics.
Chemistry: a European Journal
12
, 2658-2662.
[33] Spring, D. R. (2005). Chemical genetics to chemical genomics: small molecules offer big
insights.
Chemical Society Reviews
34
, 472-482.
[34] Allen, J. J., and Shokat, K. M. (2006). Chemical genomics: dialed in transcriptional network
control with non-steroidal glucocorticoid receptor modulators.
ACS Chemical Biology
1
,
139-140.
[35] Kwon, H. J. (2003). Chemical genomics-based target identification and validation of
anti-angiogenic agents.
Current Medicinal Chemistry
10
, 717-736.
[36] Kwon, H. J. (2006). Discovery of new small molecules and targets towards angiogenesis via
chemical genomics approach.
Current Drug Targets
7
, 397-405.
[37] Willson, T. (2003). Chemical genomics of orphan nuclear receptors.
Ernst Schering Research
Foundation Workshop
, 29-42.
[38] Caron, P. R. (2005). Introduction to chemical genomics.
Methods in Molecular Biology
310
, 3-10.
[39] Zartler, E. R., and Shapiro, M. J. (2006). Protein NMR-based screening in drug discovery.
Current Pharmaceutical Design
12
, 3963-3972.
[40] Zartler, E. R., Yan, J., Mo, H., Kline, A. D., and Shapiro, M. J. (2003). 1D NMR methods in
ligand-receptor interactions.
Current Topics in Medicinal Chemistry
3
, 25-37.
[41] Card, G. L., Blasdel, L., England, B. P., Zhang, C., Suzuki, Y., Gillette, S., Fong, D., Ibrahim,
P. N., Artis, D. R., Bollag, G., Milburn, M. V., Kim, S.-H., Schlessinger, J., and Zhang, K.
Y. J. (2005). A family of phosphodiesterase inhibitors discovered by cocrystallography and
scaffold-based drug design.
Nature Biotechnology
23
, 201-207.
[42] Jhoti, H. (2005). A new school for screening.
Nature Biotechnology
23
, 184-6.
[43] Sanders, W. J., Nienaber, V., Lerner, C. G., McCall, J. O., Merrick, S. M., Swanson, S. J.,
Harlan, J. E., Stoll, V. S., Stamper, G. F., Betz, S. F., Condroski, K. R., Meadows, R. P.,